Document is current
Any future updates will be listed below
-
Authors
Kern, Anna Emilia
Pereyra, David
Santol, Jonas
Ammann, Markus
Kim, Sarang
Huber, Felix Xaver
Weninger, Jeremias
Brunner, Sarah
Laferl, Valerie
Herrmann, Yannic
Jankoschek, Anna
Ortmayr, Gregor
Rumpf, Benedikt
Schuetze, Marcel
Valenta, Rosmarie
Krestan, Christian
Zauner, Guenther
Zechmeister, Melanie
Skalicky, Susanna
Hackl, Matthias
Assinger, Alice
Gruenberger, Thomas
Starlinger, Patrick
-
Funding
Funding for this research was provided by:
Austrian Science Fund FWF (P-32064)
National Institute of Health (R01DK122813)
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 9 January 2025
Accepted: 5 May 2025
First Online: 5 June 2025
Disclosure
: Patrick Starlinger was involved in the development of hepatomiR®, the testing system discussed in this article and is a consultant for TAmiRNA GmbH, the company that developed hepatomiR®. Alice Assinger was involved in the development of hepatomiR®. Matthias Hackl is employed by and owns stock in TAmiRNA GmbH. Susanna Skalicky is employed by TAmiRNA GmbH.
